ECO 2026 12 - 15 May 2026

Gastrointestinal Tolerability of Once-Daily Oral Semaglutide 25 mg in Adults with Overweight or Obesity, and the Relationship with Weight Loss: A Post Hoc Analysis of the OASIS 4 Trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
Congress poster
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)